Status:
COMPLETED
Escitalopram Neuroimaging Supplement
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Body Dysmorphic Disorder
Eligibility:
All Genders
18-64 years
Brief Summary
The purpose of this study is to find out more about the brain's response to selective serotonin reuptake inhibitor (SSRIs) treatment in people with body dysmorphic disorder (BDD). The investigators wi...
Detailed Description
The investigators have chosen to focus on five regions of interest, namely ACC, OFC, caudate, amygdala and hippocampus. These are brain regions that have been previously associated with obsessive-comp...
Eligibility Criteria
Inclusion
- male or female.
- from 18-64 years of age.
- right-handed, by virtue of assessment with the Edinburgh Handedness Inventory
- capacity to render informed consent.
- already enrolled in clinical study NCT00149799.
- must be an outpatient with a primary (the condition that is most central to the patient's current distress) psychiatric diagnosis of BDD, as defined by DSM-IV criteria and by a BDD Yale-Brown Obsessive-Compulsive Scale Score greater than or equal to 24.
Exclusion
- with serious medical illness or instability for which hospitalization may be likely within four months of entry into the study, or current renal insufficiency or diabetes.
- any pregnant or lactating women or those of childbearing potential not using medically accepted forms of contraception will be excluded. Pregnancy status will be determined by administration of a blood beta-HCG test prior to each PET scan.
- with recent or anticipated radiation exposure, which, combined with the exposure in the present study, will exceed allowable annual limits for the subject
- with a history of hypersensitivity to any component of FDG
- with specific comorbid psychiatric diagnoses (alcohol abuse or dependence within the past 3 months, bipolar disorder, psychosis, organic mental disorder, development disorder, borderline personality disorder, body image concerns accounted for primarily by an eating disorder or weight concerns). If subjects have another comorbid diagnosis, the BDD must be the primary concern.
- MRI- incompatibilities (for example, metal implants, pacemakers)
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT01398865
Start Date
December 1 2008
End Date
March 1 2013
Last Update
March 13 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OCD & Related Disorders Clinic
Boston, Massachusetts, United States, 02114